Cidara ( CDTX ) Q2 Cash Surges 163%
Cidara Therapeutics ( NASDAQ:CDTX ) , a biotechnology company focused on the development of innovative therapies for infectious diseases and oncology, released its second-quarter 2025 earnings on August 7, 2025. The company reported GAAP earnings per share of $1.65.
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, July 24, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc.
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( C ) ( 4 )
SAN DIEGO, July 01, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of ...
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
SAN DIEGO, June 30, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced its addition to the Russell 2000® and Russell 3000® Indexes.
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, June 26, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( "Cidara" ) CDTX, a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced the closing of its underwritten public offering of 9,147,727 shares of ...
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, June 26, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( "Cidara" ) ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced the closing of its underwritten public offering of ...
FedEx Issues Soft Guidance, Joins Torrid Holdings, Allot And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Allot ( NASDAQ:ALLT ) , AST SpaceMobile ( NASDAQ:ASTS )
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of FedEx Corporation FDX fell sharply in today's pre-market trading following soft first-quarter guidance.
Why BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - BlackBerry ( NYSE:BB ) , Allot ( NASDAQ:ALLT )
Shares of BlackBerry Limited BB rose sharply in today's pre-market trading following first-quarter results. BlackBerry reported quarterly earnings of two cents per share, which beat the analyst consensus estimate of zero cents. Quarterly revenue of $121.7 million beat the Street estimate of ...
Cidara Announces Pricing of Upsized Public Offering of Common Stock - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, June 24, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( "Cidara" ) CDTX, a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of ...
Cidara Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, June 24, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( "Cidara" ) ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced the pricing of an underwritten public offering of ...
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday - Advance Auto Parts ( NYSE:AAP ) , Applied Mat ( NASDAQ:AMAT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs lowered Advance Auto Parts, Inc. AAP price target from $48 to $46.
Cidara Announces Proposed Public Offering of Common Stock - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, June 23, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( "Cidara" ) CDTX, a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced its plans to commence an underwritten public offering, subject to ...
Cidara Announces Proposed Public Offering of Common Stock
SAN DIEGO, June 23, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( "Cidara" ) ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced its plans to commence an underwritten public offering, ...
Crude Oil Falls 1%; US Services PMI Declines In June - Compass Pathways ( NASDAQ:CMPS ) , Cidara Therapeutics ( NASDAQ:CDTX )
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining over 50 points on Monday. The Dow traded up 0.02% to 42,216.40 while the NASDAQ gained 0.35% to 19,514.58. The S&P 500 also rose, gaining, 0.23% to 5,981.86. Consumer discretionary shares jumped by 1.6% on ...
Why Is Cidara Therapeutics Stock Trading Higher On Monday? - Cidara Therapeutics ( NASDAQ:CDTX )
CD388 showed 76.1% flu prevention efficacy at highest dose over 24 weeks. NAVIGATE trial met all primary and secondary endpoints with no safety issues. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here. Cidara Therapeutics, Inc.
Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results - Compass Pathways ( NASDAQ:CMPS ) , Cidara Therapeutics ( NASDAQ:CDTX )
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 200 points on Monday. Following the market opening Monday, the Dow traded up 0.50% to 42,417.90 while the NASDAQ gained 0.61% to 19,566.92. The S&P 500 also rose, gaining, 0.62% to 6,004.66.
Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza - Cidara Therapeutics ( NASDAQ:CDTX )
The study met its primary and all secondary efficacy endpoints for all dose groups Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo CD388 was well-tolerated with no safety signals ...
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
SAN DIEGO, May 08, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) ( the Company ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today reported financial results for the first quarter ended March 31, ...
Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics ( CDTX ) is a Great Choice
Does Cidara Therapeutics (CDTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
SAN DIEGO, April 24, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies, today announced that it will report its first quarter 2025 financial results and ...
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
FLORHAM PARK, N.J., April 16, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of ...
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors - Cidara Therapeutics ( NASDAQ:CDTX ) , Phathom Pharmaceuticals ( NASDAQ:PHAT )
FLORHAM PARK, N.J., April 16, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. PHAT, a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors.
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( C ) ( 4 ) - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, April 01, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc.
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( C ) ( 4 )
SAN DIEGO, April 01, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies, today announced that the Compensation and Human Capital Committee of its Board of ...
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - Elicio Therapeutics ( NASDAQ:ELTX )
BOSTON, March 24, 2025 ( GLOBE NEWSWIRE ) -- Elicio Therapeutics, Inc. ELTX "Elicio Therapeutics" or "Elicio" ) ) , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as ...
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics ( CDTX ) : Here's What You Should Know
The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology
Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status ...
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, March 06, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) ( the Company ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies, today reported financial results for the fourth quarter and full ...
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer
Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning companies from R&D to commercialization Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning ...
Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, Dec. 04, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc.
Cidara Therapeutics ( CDTX ) Just Flashed Golden Cross Signal: Do You Buy?
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference
SAN DIEGO, Nov. 19, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies designed to save lives and improve the standard of care for patients facing serious ...
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Cytokinetics ( NASDAQ:CYTK )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Guggenheim analyst Seamus Fernandez initiated coverage on Cidara Therapeutics, Inc.
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
SAN DIEGO, Nov. 07, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) ( the Company ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies designed to save lives and improve the standard of care for patients ...
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, Oct. 31, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc.
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( C ) ( 4 )
SAN DIEGO, Oct. 04, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies designed to save lives and improve the standard of care for patients facing serious ...
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, Sept. 25, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc.
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK ...
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
SAN DIEGO, Sept. 19, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies designed to save lives and improve the standard of care for patients facing serious ...
Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388
SAN DIEGO, Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies designed to save lives and improve the standard of care for patients facing serious ...
Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, Sept. 05, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc.
Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, Aug. 19, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc.
Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer
Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team ...
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
SAN DIEGO, Aug. 13, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) ( the Company ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies designed to save lives and improve the standard of care for patients ...
BK Virus Infection Market to Witness Surge in Growth During the Study Period ( 2020-2034 ) | DelveInsight
The BK virus infection market is expanding due to increased awareness and advancements in diagnostic technologies. Rising kidney transplant procedures and the subsequent need for effective treatments and management of BK virus in immunocompromised patients are driving market growth.
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, July 03, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies designed to save lives and improve the standard of care for patients facing serious ...
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
SAN DIEGO, May 30, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies designed to save lives and improve the standard of care for patients facing serious ...
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
SAN DIEGO, May 15, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) ( the Company ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies designed to save lives and improve the standard of care for patients ...
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, May 15, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc.
CDTX INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX - Cidara Therapeutics ( NASDAQ:CDTX )
NEW YORK, May 14, 2024 ( GLOBE NEWSWIRE ) -- WHY: New York, N.Y., May 14, 2024. Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc.
